Zhongsheng Pharmaceutical announced on the evening of October 7 that ZSP1601 tablets, a Class 1 innovative drug independently developed by its controlling subsidiary Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd., have been included in the Breakthrough Therapy Designation by the Center for Drug Evaluation of the National Medical Products Administration. The drug is intended for the treatment of metabolic dysfunction-associated steatohepatitis, or MASH, and is a first-in-class innovative drug with global independent intellectual property rights and a novel mechanism of action for treating MASH.
Guangdong Zhongsheng Pharmaceutical Co LtdZSP1601 tablets, developed by its controlling subsidiary, received Breakthrough Therapy Designation from the NMPA for treating MASH.
